Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Biochemistry

Background:

• Chronic kidney disease (CKD) is associated with reduced nitric oxide (NO) production and bioavailability.
• This reduction in NO action may contribute to hypertension, cardiovascular disease (CVD), and CKD progression.
• The precise molecular mechanisms underlying diminished NO action in CKD require further investigation.

Purpose of the Study:

• To review the molecular mechanisms behind elevated asymmetric dimethylarginine (ADMA) in CKD.
• To discuss the pathophysiological role of ADMA in cardiovascular disease (CVD) among high-risk patients, particularly those with CKD.
• To explore ADMA as a potential link between CKD and CVD.

Main Methods:

• Literature review focusing on studies investigating ADMA levels and function in CKD.
• Analysis of molecular mechanisms related to ADMA production and its inhibitory effects on NO synthase.
• Examination of ADMA as a biomarker for cardiovascular events and renal injury progression in CKD.

Main Results:

• Plasma levels of ADMA are elevated in patients with CKD.
• Elevated ADMA acts as an endogenous inhibitor of NO synthase, reducing NO bioavailability.
• Increased ADMA levels are a strong predictor of future cardiovascular events and renal injury progression in CKD.

Conclusions:

• Elevated ADMA may represent a key factor connecting cardiovascular disease (CVD) and chronic kidney disease (CKD).
• Understanding ADMA's role is crucial for managing cardiovascular risk in CKD patients.
• Further research into ADMA metabolism and therapeutic targeting is warranted.